We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil. In this article, we are going ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a ...

Fintel reports that on March 14, 2025, Oppenheimer upgraded their outlook for Nektar Therapeutics (NasdaqCM:NKTR) from ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a research report issued on ...

EDT Nektar (NKTR) files $300M mixed securities shelfLight Up your Portfolio with Spark:Easily identify stocks' risks and opportunities.

In this article, we are going to take a look at where Nektar Therapeutics (NASDAQ:NKTR) stands against other stocks that Wall Street is calling bullish amid market turmoil. The S&P 500 is down 8.6 ...

Rahimi covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Tectonic Therapeutic, and Madrigal Pharmaceuticals. According to TipRanks, Rahimi has an average return of -0.8 ...

Analysts at William Blair raised their Q1 2025 EPS estimates for Nektar Therapeutics in a research report issued to clients and investors on Thursday, March 13th. William Blair analyst A. Hsieh now ...

Welcome to the Nektar Therapeutics Fourth Quarter 2024 financial ... First, we continue to advance our novel TNFR2 agonist antibody program, NKTR-0165. IND-enabling studies are ongoing with ...